638 related articles for article (PubMed ID: 26277543)
1. MYC and metabolism on the path to cancer.
Hsieh AL; Walton ZE; Altman BJ; Stine ZE; Dang CV
Semin Cell Dev Biol; 2015 Jul; 43():11-21. PubMed ID: 26277543
[TBL] [Abstract][Full Text] [Related]
2. Oncogenes strike a balance between cellular growth and homeostasis.
Qiu B; Simon MC
Semin Cell Dev Biol; 2015 Jul; 43():3-10. PubMed ID: 26277544
[TBL] [Abstract][Full Text] [Related]
3. MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.
Shukla SK; Gunda V; Abrego J; Haridas D; Mishra A; Souchek J; Chaika NV; Yu F; Sasson AR; Lazenby AJ; Batra SK; Singh PK
Oncotarget; 2015 Aug; 6(22):19118-31. PubMed ID: 26046375
[TBL] [Abstract][Full Text] [Related]
4. A Time for MYC: Metabolism and Therapy.
Dang CV
Cold Spring Harb Symp Quant Biol; 2016; 81():79-83. PubMed ID: 28174256
[TBL] [Abstract][Full Text] [Related]
5. Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1).
Liu B; Huang ZB; Chen X; See YX; Chen ZK; Yao HK
Cell Mol Neurobiol; 2019 Apr; 39(3):415-434. PubMed ID: 30771196
[TBL] [Abstract][Full Text] [Related]
6. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
7. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
8. Harnessing impaired energy metabolism in cancer cell: small molecule- mediated ways to regulate tumorigenesis.
Govardhan KS; Ramyasri K; Kethora D; Ravishekar Y; Prasenjit M
Anticancer Agents Med Chem; 2011 Mar; 11(3):272-9. PubMed ID: 21434854
[TBL] [Abstract][Full Text] [Related]
9. PKM2 contributes to cancer metabolism.
Wong N; Ojo D; Yan J; Tang D
Cancer Lett; 2015 Jan; 356(2 Pt A):184-91. PubMed ID: 24508027
[TBL] [Abstract][Full Text] [Related]
10. Impact of MYC in regulation of tumor cell metabolism.
Wahlström T; Henriksson MA
Biochim Biophys Acta; 2015 May; 1849(5):563-9. PubMed ID: 25038584
[TBL] [Abstract][Full Text] [Related]
11. Translational control by mTOR-independent routes: how eIF6 organizes metabolism.
Miluzio A; Ricciardi S; Manfrini N; Alfieri R; Oliveto S; Brina D; Biffo S
Biochem Soc Trans; 2016 Dec; 44(6):1667-1673. PubMed ID: 27913676
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic role of natural compounds in mTOR-mediated metabolic reprogramming.
Cerella C; Gaigneaux A; Dicato M; Diederich M
Cancer Lett; 2015 Jan; 356(2 Pt A):251-62. PubMed ID: 24530513
[TBL] [Abstract][Full Text] [Related]
13. Measuring MYC-Mediated Metabolism in Tumorigenesis.
Tang HY; Goldman AR; Zhang X; Speicher DW; Dang CV
Methods Mol Biol; 2021; 2318():231-239. PubMed ID: 34019293
[TBL] [Abstract][Full Text] [Related]
14. Her4 promotes cancer metabolic reprogramming via the c-Myc-dependent signaling axis.
Han J; Zhang Y; Xu J; Zhang T; Wang H; Wang Z; Jiang Y; Zhou L; Yang M; Hua Y; Cai Z
Cancer Lett; 2021 Jan; 496():57-71. PubMed ID: 33038488
[TBL] [Abstract][Full Text] [Related]
15. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of differentiation 1 transcription factor promotes metabolic reprogramming in hepatocellular carcinoma cells.
Sharma BK; Kolhe R; Black SM; Keller JR; Mivechi NF; Satyanarayana A
FASEB J; 2016 Jan; 30(1):262-75. PubMed ID: 26330493
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism.
Dang CV
Cold Spring Harb Symp Quant Biol; 2011; 76():369-74. PubMed ID: 21960526
[TBL] [Abstract][Full Text] [Related]
18. Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer.
Li C; Zhang G; Zhao L; Ma Z; Chen H
World J Surg Oncol; 2016 Jan; 14(1):15. PubMed ID: 26791262
[TBL] [Abstract][Full Text] [Related]
19. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
Sipos F; Firneisz G; Műzes G
World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
